
Dr. Zhang on risk stratification and treatment selection in mCSPC
Risk factors Dr.Zhang highlights include site of metastases, PSA response, and metastases burden.
Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.
Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















